Acacia Pharma wins BEL Company of the Year for the second consecutive year
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge (United Kingdom) and Utrecht (the Netherlands) – Acacia Pharma Group plc (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that it has been awarded BEL Small Company of the Year 2020 by Euronext Brussels at its annual New Year’s Ceremony held virtually last night. This is the second consecutive year that Acacia Pharma has won this award.
“We are delighted to be recognized again with this award. 2020 has been a very successful year for Acacia Pharma, having gained approval for two new products in the US: BARHEMSYS®, a new antiemetic for surgical patients to treat post-operative nausea & vomiting, and BYFAVO™, a rapid acting and reversible sedative for patients requiring moderate sedation to undergo short medical procedures. We launched BARHEMSYS in August and are in the very final stages of the launch process for BYFAVO, which we expect to complete imminently,” commented Mike Bolinder, CEO of Acacia Pharma.
Mr. Bolinder added: “Looking to the future, our strategy is to drive the sales of both products in the US through our own organization and we believe we are well positioned for success. This potential success has been recognized in the recent initiation of coverage of the company by the healthcare analysts at Jefferies, who included Acacia Pharma as one of their top European biopharma/biotech investment ideas for 2021. We are pleased with the progress we have been able to make during the last year, especially given the impact of the global Covid-19 pandemic during the same period.”
The annual New Year’s Ceremony recognizes the best performing companies on Euronext Brussels. The BEL Small Company of the Year is awarded to a company that has demonstrated the highest relative increase in market capitalization, within the BEL Small index in 2020. The award was announced by the CEO of Euronext Brussels, Vincent Van Dessel, in the presence of Vincent Van Peteghem, Belgian Deputy Prime Minister and Minister of Finance.
Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
Mark Swallow, Frazer Hall, David Dible
Citigate Dewe Rogerson
+44 20 7638 9571
Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV).
BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH. For more information, visit the company's website at www.acaciapharma.com.
About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over $1.5 billion across two fund strategies: Venture & Growth and Private Equity.
Gilde Healthcare Venture & Growth invests in fast growing companies active in digital health, MedTech and therapeutics. The Venture & Growth companies are based in Europe and North America.
Gilde Healthcare Private Equity participates in profitable European lower mid-market healthcare companies with a prime focus on the Benelux and DACH region. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.
For more information, visit the company's website at www.gildehealthcare.com.
Forward looking statements
This announcement includes forward-looking statements, which are based on current expectations and projections about future events. These statements may include, without limitation, any statements preceded by, followed by or including words such as "believe", "expect", "intend", "may", "plan", "will", "should", "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements may and often do differ materially from actual results. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and investments, including, among other things, the development of its business, trends in its operating industry, and future capital expenditures and acquisitions. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's business, results of operations, financial position, prospects, growth or strategies and the industry in which it operates. Save as required by law or applicable regulation, the Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise. Forward-looking statements speak only as of the date they are made.